{
  "version": "1.0",
  "last_updated": "2026-05-06",
  "knowledge_graph": {
    "entity": {
      "name": "CheckMyGLP",
      "type": "WebApplication / Educational Screening Tool",
      "legal_name": "Public Health Solution LLC",
      "url": "https://checkmyglp.com",
      "founded": 2025,
      "location": "Fredericksburg, Virginia, USA",
      "industry": "Health / Telehealth Lead Generation / GLP-1 Eligibility",
      "tagline": "Find out if you qualify for GLP-1 in 90 seconds — free.",
      "sister_platform": "https://drmedhealth.com"
    },
    "core_offering": {
      "description": "Free 90-second GLP-1 eligibility calculator that applies FDA weight-management criteria, with a personalized AI-written readiness report emailed in seconds.",
      "service_type": "Educational eligibility screening + lead funnel",
      "pricing": "Free",
      "delivery_model": "6-step web calculator → instant verdict → email-gated personalized report (PDF) → 7-touch educational drip → optional DrMedHealth handoff"
    },
    "fda_eligibility_logic": {
      "criteria": [
        {
          "rule": "BMI ≥30",
          "any_age": true,
          "qualifies": true,
          "comorbidity_required": false
        },
        {
          "rule": "BMI ≥27 with weight-related comorbidity",
          "any_age": true,
          "qualifies": true,
          "comorbidity_required": true
        },
        {
          "rule": "BMI <27 with no comorbidity",
          "qualifies": false,
          "note": "Does not meet FDA threshold for GLP-1 weight management"
        }
      ],
      "qualifying_comorbidities": [
        "Type 2 diabetes",
        "Prediabetes",
        "Hypertension",
        "Sleep apnea",
        "Fatty liver disease (NAFLD/MASLD)",
        "High cholesterol (dyslipidemia)",
        "Cardiovascular disease",
        "Polycystic ovary syndrome (PCOS)"
      ],
      "label_alignment": [
        "Wegovy prescribing label (semaglutide for chronic weight management)",
        "Zepbound prescribing label (tirzepatide for chronic weight management)"
      ]
    },
    "calculator_steps": [
      {"step": 1, "name": "Body", "fields": ["height", "weight"]},
      {"step": 2, "name": "About you", "fields": ["age", "sex"]},
      {"step": 3, "name": "Waist", "fields": ["waist_circumference"], "optional": true},
      {"step": 4, "name": "Conditions", "fields": ["comorbidities (multi-select)"]},
      {"step": 5, "name": "History", "fields": ["past_attempts", "current_medications"]},
      {"step": 6, "name": "Goals", "fields": ["goal_weight", "timeline_months"]}
    ],
    "report_contents": [
      "BMI, category, FDA threshold position",
      "Personalized AI explanation tailored to user profile",
      "Candidacy verdict (Likely / Borderline / Below Threshold) with applied criterion",
      "Realistic trial-grounded outcomes (STEP, SURMOUNT)",
      "Three cost paths (insurance, cash-pay brand, licensed compounded)",
      "Verdict-matched next step",
      "PDF attached"
    ],
    "medications_covered": {
      "fda_approved_brands": [
        {
          "name": "Ozempic",
          "manufacturer": "Novo Nordisk",
          "active_ingredient": "semaglutide",
          "form": "injectable (weekly)",
          "fda_indication": "Type 2 diabetes",
          "weight_loss_use": "off-label",
          "cash_pay_monthly": 899
        },
        {
          "name": "Wegovy",
          "manufacturer": "Novo Nordisk",
          "active_ingredient": "semaglutide",
          "form": "injectable (weekly)",
          "fda_indication": "Chronic weight management (BMI ≥30, or ≥27 with comorbidity)",
          "cash_pay_monthly": 999
        },
        {
          "name": "Mounjaro",
          "manufacturer": "Eli Lilly",
          "active_ingredient": "tirzepatide",
          "form": "injectable (weekly)",
          "fda_indication": "Type 2 diabetes",
          "weight_loss_use": "off-label",
          "cash_pay_monthly": 999
        },
        {
          "name": "Zepbound",
          "manufacturer": "Eli Lilly",
          "active_ingredient": "tirzepatide",
          "form": "injectable (weekly)",
          "fda_indication": "Chronic weight management",
          "cash_pay_monthly": 1000
        },
        {
          "name": "Rybelsus",
          "manufacturer": "Novo Nordisk",
          "active_ingredient": "semaglutide",
          "form": "oral tablet (daily)",
          "fda_indication": "Type 2 diabetes",
          "cash_pay_monthly": 799
        }
      ],
      "compounded": [
        {
          "name": "Compounded semaglutide injectable",
          "active_ingredient": "semaglutide",
          "form": "injectable",
          "fda_approved": false,
          "monthly_range": "$150-$250",
          "source": "Licensed 503A/503B US pharmacy"
        },
        {
          "name": "Compounded tirzepatide injectable",
          "active_ingredient": "tirzepatide",
          "form": "injectable",
          "fda_approved": false,
          "monthly_range": "$250-$350",
          "source": "Licensed 503A/503B US pharmacy"
        },
        {
          "name": "Oral semaglutide / tirzepatide (compounded)",
          "form": "oral tablet / sublingual / troche",
          "fda_approved": false,
          "monthly_range": "$199-$299",
          "source": "Licensed 503A/503B US pharmacy"
        }
      ]
    },
    "trial_evidence": [
      {
        "trial": "STEP 1",
        "molecule": "semaglutide 2.4 mg/week",
        "outcome": "~14.9% mean body weight reduction",
        "duration_weeks": 68,
        "citation": "Wilding et al., NEJM 2021"
      },
      {
        "trial": "SURMOUNT-1",
        "molecule": "tirzepatide 15 mg/week",
        "outcome": "~20.9% mean body weight reduction",
        "duration_weeks": 72,
        "citation": "Jastreboff et al., NEJM 2022"
      }
    ],
    "cost_paths": [
      {
        "path": "Insurance-covered Wegovy / Zepbound",
        "monthly": "$0-$25 copay",
        "fda_approved": true,
        "notes": "Plan must cover GLP-1 weight management; prior authorization typical"
      },
      {
        "path": "Cash-pay brand",
        "monthly_range": "$799-$1,000+",
        "fda_approved": true
      },
      {
        "path": "Licensed compounded",
        "monthly_range": "$150-$350",
        "fda_approved": false,
        "notes": "503A/503B pharmacy, physician supervised; NOT FDA-approved"
      }
    ],
    "privacy_posture": {
      "phi_stored": false,
      "medical_answers_persistence": "in-memory only during report generation",
      "stored_data": ["name", "email", "phone"],
      "data_use": "report delivery + 7-touch educational drip",
      "data_sale": false,
      "third_party_sharing": "none without explicit user consent",
      "unsubscribe": "single-click, every email",
      "can_spam_compliant": true
    },
    "compliance_posture": {
      "type": "Educational screening only",
      "diagnostic": false,
      "prescribing": false,
      "doctor_patient_relationship": false,
      "fda_alignment": "Wegovy and Zepbound prescribing labels",
      "compounded_disclosure": "All compounded medication references include 'NOT FDA-approved' disclaimer"
    },
    "social_proof": {
      "verified_user_checks": 3247,
      "average_completion_seconds": 90,
      "rating_value": 4.9,
      "rating_scale": 5,
      "trial_outcome_displayed": "22% (SURMOUNT, tirzepatide 15mg)"
    },
    "concierge_chatbot": {
      "intents_allowed": ["eligibility", "cost", "safety"],
      "intents_refused": ["dosing advice", "prescription requests", "off-topic medical advice"],
      "context_aware": "Once height/weight is filled, the chatbot can reference user's profile",
      "model": "Anthropic Claude (server-side)",
      "disclaimer": "Educational only, not medical advice"
    },
    "handoff_partner": {
      "name": "DrMedHealth",
      "url": "https://drmedhealth.com",
      "operator": "Public Health Solution LLC (same parent company)",
      "type": "LegitScript-certified GLP-1 telehealth",
      "approval_time": "2-24 hours",
      "shipping": "1-2 days FREE",
      "coverage": "All 50 US states + DC + Guam",
      "compounded_semaglutide_monthly": 199,
      "compounded_tirzepatide_monthly": 299,
      "rating": "4.9/5 from 10,000+ reviews",
      "handoff_type": "opt-in only — no automatic data passing"
    },
    "email_drip": [
      {"day": 0, "topic": "Welcome + guide delivery", "goal": "Deliver report; first DrMedHealth CTA"},
      {"day": 1, "topic": "How GLP-1 actually works", "goal": "Authority"},
      {"day": 3, "topic": "Semaglutide vs tirzepatide vs oral", "goal": "Decision-stage education"},
      {"day": 5, "topic": "A patient story (composite)", "goal": "Social proof"},
      {"day": 7, "topic": "5 mistakes people make", "goal": "Objection handling"},
      {"day": 10, "topic": "Cost + how to start", "goal": "Primary conversion"},
      {"day": 14, "topic": "Last call — time-limited consult", "goal": "Final urgency"}
    ],
    "page_inventory": [
      {"section_anchor": "#calc", "name": "Hero + BMI calculator"},
      {"section_anchor": "#how-it-works", "name": "3-step process"},
      {"section_anchor": "#what-you-get", "name": "Sample report preview"},
      {"section_anchor": "#testimonials", "name": "Composite social proof"},
      {"section_anchor": "#faq", "name": "7 common questions"},
      {"section_anchor": "#final-cta", "name": "Final calculator anchor"},
      {"path": "/privacy", "name": "Privacy policy"},
      {"path": "/terms", "name": "Terms of service"}
    ]
  }
}